Deutsche Bank’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-66,445
| Closed | -$1.42M | – | 3742 |
|
|
2026
Q1 | $1.42M | Buy |
66,445
+9,435
| +17% | +$133K | ﹤0.01% | 1975 |
|
|
2025
Q4 | $531K | Buy |
57,010
+15,506
| +37% | +$130K | ﹤0.01% | 2533 |
|
|
2025
Q3 | $293K | Sell |
41,504
-283,784
| -87% | -$1.95M | ﹤0.01% | 2865 |
|
|
2025
Q2 | $2.11M | Sell |
325,288
-9,234
| -3% | -$63.5K | ﹤0.01% | 1670 |
|
|
2025
Q1 | $2.65M | Sell |
334,522
-24,398
| -7% | -$263K | ﹤0.01% | 1569 |
|
|
2024
Q4 | $4.55M | Buy |
358,920
+35,460
| +11% | +$493K | ﹤0.01% | 1374 |
|
|
2024
Q3 | $4.51M | Buy |
323,460
+121,593
| +60% | +$1.73M | ﹤0.01% | 1316 |
|
|
2024
Q2 | $2.78M | Buy |
201,867
+23,693
| +13% | +$347K | ﹤0.01% | 1482 |
|
|
2024
Q1 | $2.94M | Buy |
178,174
+1,018
| +0.6% | +$15.2K | ﹤0.01% | 1481 |
|
|
2023
Q4 | $2.59M | Buy |
177,156
+19
| +0% | +$230 | ﹤0.01% | 1543 |
|
|
2023
Q3 | $2.17M | Buy |
177,137
+9,219
| +5% | +$120K | ﹤0.01% | 1322 |
|
|
2023
Q2 | $2M | Sell |
167,918
-417
| -0.2% | -$5.45K | ﹤0.01% | 1622 |
|
|
2023
Q1 | $2.25M | Buy |
168,335
+151,525
| +901% | +$2.96M | ﹤0.01% | 1625 |
|
|
2022
Q4 | $362K | Buy |
16,810
+5,212
| +45% | +$107K | ﹤0.01% | 2624 |
|
|
2022
Q3 | $232K | Buy |
11,598
+554
| +5% | +$11.8K | ﹤0.01% | 2861 |
|
|
2022
Q2 | $198K | Sell |
11,044
-2,219
| -17% | -$22.9K | ﹤0.01% | 3177 |
|
|
2022
Q1 | $132K | Buy |
13,263
+6,561
| +98% | +$86.7K | ﹤0.01% | 3471 |
|
|
2021
Q4 | $113K | Buy |
6,702
+363
| +6% | +$7.46K | ﹤0.01% | 3652 |
|
|
2021
Q3 | $150K | Buy |
+6,339
| New | +$152K | ﹤0.01% | 3704 |
|
Other funds holding DAWN
Deutsche Bank's DAWN Position: Q2 2026 in Review
Deutsche Bank sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 66,445 shares — an estimated $1.42M sold.
Deutsche Bank first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $4.55M in Q4 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Deutsche Bank reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Deutsche Bank sold 66,445 Day One Biopharmaceuticals shares in Q2 2026, an estimated $1.42M.
- Deutsche Bank first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
- Deutsche Bank's Day One Biopharmaceuticals position peaked at $4.55M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.